136 related articles for article (PubMed ID: 25264883)
1. Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.
Pan YQ; Shi WW; Xu DP; Xu HH; Zhou MY; Yan WH
Chin Med Sci J; 2014 Sep; 29(3):156-61. PubMed ID: 25264883
[TBL] [Abstract][Full Text] [Related]
2. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
4. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
6. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.
Shoji F; Yoshino I; Yano T; Kometani T; Ohba T; Kouso H; Takenaka T; Miura N; Okazaki H; Maehara Y
Cancer; 2007 Dec; 110(12):2793-8. PubMed ID: 17941001
[TBL] [Abstract][Full Text] [Related]
7. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
10. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
[TBL] [Abstract][Full Text] [Related]
11. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.
Jin B; Dong Y; Wang HM; Huang JS; Han BH
Acta Pharmacol Sin; 2014 Mar; 35(3):373-80. PubMed ID: 24487967
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
13. Correlation between pre-treatment serum carcinoembryonic antigen levels and genotypes in a large population of Chinese people with advanced lung adenocarcinoma.
Liu J; Zhao YQ; Han X; Hu XF; Wu HB; Chen LJ; Song YP
Intern Med J; 2019 May; 49(5):634-643. PubMed ID: 30379408
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.
Ono A; Takahashi T; Mori K; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Nakajima T; Endo M; Yamamoto N
BMC Cancer; 2013 Jul; 13():354. PubMed ID: 23879483
[TBL] [Abstract][Full Text] [Related]
15. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
[No Abstract] [Full Text] [Related]
16. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
17. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
[TBL] [Abstract][Full Text] [Related]
18. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
19. Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers.
Yang ZM; Ding XP; Pen L; Mei L; Liu T
Asian Pac J Cancer Prev; 2014; 15(8):3451-5. PubMed ID: 24870738
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]